贝塔阻断剂编年史:从过去的原则到现在的实践 - - 对印度次大陆的影响
Saumitra Ray1, Banshi Saboo2, Debabrata Roy3
1Department of Cardiac Sciences, AMRI Hospital, Kolkata, West Bengal, India.
Indian heart journal
|November 3, 2025
概括
贝塔抑制剂已经发展成为精确的心血管疗法. 像比索普罗洛尔这样的现代药物为各种心脏病提供了个性化治疗,改善了患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- β抑制剂已经从基本的心血管药物演变为复杂的向疗法.
- 了解上腺激素调节推动了β-阻断剂开发的进步,从非选择性剂到高度选择性剂.
研究的目的:
- 审查β-阻断剂在心血管医学中的演变和当前作用.
- 突出下一代β抑制剂 (如比索普罗罗尔和内比沃罗尔) 在管理多样化的患者群体和并发症方面的好处.
主要方法:
- 关于β抑制剂的演变,药理动力学和临床应用的文献综述.
- 对当前全球和国家关于使用β-阻断剂的指导方针的分析.
- 在印度背景下检查处方趋势.
主要成果:
- β抑制剂对于高血压,冠状动脉综合征,心律失常和心力衰竭至关重要.
- 下一代药物,如比索普罗罗尔和内比沃罗尔,具有高β1选择性,更好的耐受性和心脏保护作用.
- 比索普罗洛尔是印度高度处方的β-阻断剂,证明了临床的信任和相关性.
结论:
- 贝塔阻断剂仍然是必不可少的心血管药物,新的选择使个性化治疗成为可能.
- 高β1选择性药物,如比索普罗罗尔,推用于心痛,心脏病后的二次预防和心律失常率控制.
- 来自印度的区域数据强调了β-阻断剂在优化整个亚洲心血管结果方面的重要性.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.3K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.3K
Antihypertensive Drugs: Types of β-Blockers
1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K


